Development trends for therapeutic antibody fragments

@article{Nelson2009DevelopmentTF,
  title={Development trends for therapeutic antibody fragments},
  author={Aaron L A Nelson and Janice M. Reichert},
  journal={Nature Biotechnology},
  year={2009},
  volume={27},
  pages={331-337}
}
Monoclonal antibodies (mAbs) are an increasingly important class of therapeutic agents. Twenty-two mAbs have been approved for therapeutic use in the United States, and over 200 mAb candidates are in the clinical pipeline1. The approved products accounted for ~$20 billion of healthcare spending in 2006 (ref. 2), and the market is growing at ~14% per year3. Eight mAbs had sales >$1 billion in 2007, with Rituxan (rituximab; Genentech, S. San Francisco, CA, USA) being the bestseller, with sales of… CONTINUE READING
90 Citations
1 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 90 extracted citations

References

Publications referenced by this paper.

age of antibody fragments in the clinic that target cancer antigens unrelated to immunity

  • R. K. Jain
  • Cancer Res
  • 1988

Similar Papers

Loading similar papers…